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Abstract
Background: The function of deiodinases – selenoproteins converting thyroid hormones may be disturbed by
oxidative stress accompanying heart failure. Selenium (Se) may be used by glutathione peroxidase, leading to a lack
of deiodinase and triiodothyronine (T3). The aim of the study was the evaluation of the prevalence and clinical
significance of low T3 syndrome in heart failure and the assessment of the association of low fT3 and Se deficiency.
Methods: The study group consisted of 59 consecutive patients hospitalized due to decompensated HFrEF NYHA
III or IV. Exclusion criteria were: thyroid dysfunction, severe systemic disease, treatment with amiodarone, steroids or
propranolol. Group A included 9 patients with low free T3 (fT3) concentration below 3.1 pmol/L. Group B consisted
of the remaining 50 patients with normal fT3 levels.
Results: The prevalence of low T3 syndrome was 15.3%. The prevalence of Se deficiency was 74.6%. We
demonstrated correlations between fT3 and main clinical variables (i.e. NT-proBNP, LVEF, hsCRP), but we did not
find correlation between fT3 and the Se level. Kaplan-Meier survival analysis showed lower survival probability in
patients with low fT3 (p < 0.001).
Conclusions: Low T3 syndrome is frequently found in patients with HFrEF and is associated with a poor outcome.
We did not identify any significant correlation between Se and fT3 level.
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Background
It has been proven that either hyperthyroidism or
hypothyroidism has a harmful influence on the cardio-
vascular system and can lead to heart failure (HF) [1].
However, advanced HF is a complex multiorgan syn-
drome leading to many hormonal and immunologic al-
terations including low triiodothyronine (T3) syndrome
characterized by low triiodothyronine, elevated or nor-
mal reverse triiodothyronine (rT3) and normal or
slightly disturbed thyroid stimulating hormone (TSH)
and tetraiodothyronine (T4) levels [1–3]. T3 is the active
hormone in peripheral cells, while T4 is a prohormone
[4, 5]. HF may be associated with lowered T3 concentra-
tion in 24.5% of HF patients [6]. Several mechanisms
may cause disturbances of T4 to T3 conversion. One of
them may be decreased activity of deiodinase 1 (D1) and
increased expression and activity of deiodinase 3 (D3).
Increased expression of the D3 gene (DIO3) may occur
due to hypoxia and inflammation [7, 8].
There is also a hypothesis that the function of deiodi-
nases may be disturbed by oxidative stress and selenium
(Se) deficiency accompanying HF. The role of oxidative
stress in the onset and development of cardiovascular
diseases is widely described. Heart failure may lead to an
imbalance between pro-oxidant and anti-oxidant
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enzymes leading to an excess of reactive oxidant species
(ROS). There is growing evidence that ROS may lead to
nitric oxide synthase uncoupling, lipid peroxidation,
endothelial dysfunction, vascular smooth muscle growth,
inflammatory molecules enhancement, DNA oxidative
damage and platelet activation [9]. The above may
contribute to the progression of HF.
Glutathione peroxidase (GPX) may be considered an
oxidative stress defense marker. Se levels correlate with
GPX enzymatic activity [10, 11]. Deiodinases and GPX
are selenoproteins competing for Se [5]. This is why Se
deficiency may lead to both GPX deficiency and im-
paired T4 to T3 conversion. Both phenomena may be
caused by advanced HF. On the other hand, oxidative
stress and low T3 syndrome may contribute to HF pro-
gression [11].
Low T3 syndrome accompanying HF can cause many
disturbances. Lack of thyroid hormones (TH) may cause
downregulation of the myosin heavy chain α (α-MHC)
gene expression (MYH6), leading to a deterioration of
systolic function of the heart. TH deficiency contributes
to a decrease in sarcoplasmic/endoplasmic reticulum
calcium ATPase2 (SERCa2) by downregulation of the
ATP2A2 gene. The increase in its inhibitor – fosfolam-
ban (PLN), caused by the PLN gene upregulation, may
decrease calcium reuptake during diastole, causing
myocardial relaxation impairment. TH activate phos-
phatidylinositol 3-kinase (PI3K) and serine/threonine-
protein kinase (AKT) signaling pathways by nongenomic
action, inducing production of endothelial nitric oxide
[1, 12, 13]. In addition, TH (especially T3) have a direct
concentration-dependent vasodilatory effect [14]. Also, a
low level of TH may affect the function of ion channels,
leading to arrhythmia [1, 12, 13]. TH deficiency may
affect cardiac mitochondrial biogenesis [15]. Many of the
above mechanisms may potentially worsen the clinical
course of HF. However, the clinical significance of low
T3 syndrome is poorly studied.
A few studies suggest maladaptive character of low T3
syndrome. One study showed that low T3 syndrome is a
prognostic predictor of death in patients with heart dis-
eases [16]. A few studies suggest that low T3 levels are
associated with HF severity and are more prevalent in
NYHA class III-IV [16]. A low T3 level was shown to be
a predictor of prolonged hospital stay [17], all-cause and
cardiac mortality in HF [18–20]. Several studies showed
that low fT3 concentration may have a similar prognos-
tic value as NT-proBNP in chronic and acute HF [21–
24]. However, the coincidence of low T3 syndrome and
selenium deficit was not tested in HF patients. The aim
of the study was the evaluation of the prevalence and
clinical significance of low T3 syndrome in decompen-
sated HF and the relation of low fT3 to selenium
deficiency.
Methods
Study population
The study protocol of this prospective cohort study was ap-
proved by the Ethics Committee. All procedures performed
in studies involving human participants were in accordance
with the ethical standards of the Helsinki Declaration. From
June of 2015 to August of 2017 we prospectively evaluated
59 consecutively hospitalized patients who gave written in-
formed consent and fulfilled the inclusion criteria: decom-
pensated heart failure with reduced ejection fraction
(HFrEF), NYHA class III or IV. The diagnosis was made ac-
cording to the ESC Guidelines for the diagnosis and treat-
ment of acute and chronic heart failure [25]. Exclusion
criteria were: admission due to acute coronary syndrome,
previous or current thyroid disease (abnormalities in thy-
roid physical examination, abnormal thyroid morphology
ascertained by previous imaging tests, abnormal serum
level of TSH at admission, subclinical or overt hyperthy-
roidism, subclinical or overt hypothyroidism, treatment
with amiodarone, glucocorticosteroids and/or propranolol),
clinical evidence of severe systemic disease (e.g., inflamma-
tory or autoimmune disease, neoplasm, chronic renal dis-
ease (GFR < 30ml/min/1,73m2). All the patients received
optimal medical treatment. Depending on fT3 concentra-
tion, 2 study groups were distinguished: Group A consist-
ing of patients with a fT3 concentration below the normal
limit and Group B with normal fT3 plasma levels.
Biochemical tests
Serial blood samples were collected to assess the thyroid
profile, as well as to carry out biochemical and hematology
testing. On the 1st and 3rd day of hospitalization and on
the follow-up visit the patients had laboratory tests such as
TSH [electrochemiluminescent immunoassay (ECLIA)
method, sandwich test], free tetraiodothyronine (fT4), free
triiodothyronine (fT3) [electrochemiluminescent immuno-
assay (ECLIA) method, competitive test], rT3 [radioisotope
method] was determined on the 3rd day of hospitalization.
Reference values in our laboratory were: TSH (0.27–
4.2 μIU/ml), fT3 (3.10–6.80 pmol/L), fT4 (12.0–22.0
pmol/L), rT3 (0,09–0,35 ng/ml).
NT-proBNP [electrochemiluminescent immunoassay
(ECLIA) method, sandwich test] levels were analyzed on the
1st and 3rd day of hospitalization and on the follow-up visit.
The reference value for NT-proBNP in our laboratory is <
125.0 pg/ml. Serum markers of inflammatory state: hsCRP
[immunoturbodimetric method] and white blood count
(WBC) [Hydro Dynamic Focusing flow cytometry method]
were performed on the 1st and 3rd day of hospitalization.
Creatinine levels [Jaffé Gen.2 method, rate blanked, com-
pensated] and eGFR/CKD-EPI/ were assessed at admission.
Samples for serum selenium level were taken on the
3rd day of hospitalization using the Vacutainer system.
After collection, blood was left to clot for at least 30
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min. Before 120 min after collection, the samples were
centrifuged for serum separation (1300G, 12 min). After
that, the serum samples were frozen at − 80 C. On the day
of analysis, samples were thawed and centrifuged (5000G,
5min). Inductively coupled plasma mass spectrometry
(ICP-MS) was used for analyses. Selenium determination
was performed on the ICP mass spectrometer NexION
350D (PerkinElmer, Shelton, USA). The spectrometer was
equipped with dynamic reaction cell operating with
high-purity methane. It was calibrated using an external
calibration technique. Calibration standards were prepared
from 10 μg/ml Multi-Element Calibration Standard 3 (Per-
kinElmer, Shelton, USA) by diluting with to the final con-
centration of 0,1; 0,5; 1,0; 2,0; 5,0; 10 μg/l. Correlation
coefficients for calibration curves were always greater than
0,999. An analysis protocol assumed 100-fold dilution of
serum in blank reagent. Blank reagent consists of 10ml of
65% Suprapur Grade nitric acid (Merck, Germany), 0,20ml
of Triton X-100 (PerkinElmer, USA) filled to the mark of 1
l flask with class I deionized water (Merck Millipore). The
Germanium isotope (Ge74) was set as the internal standard.
Reference values of selenium in the local laboratory
were: females < 50 years old (75.0–85.0 μg/l), females >
50 years old (65.0–75.0 μg/l), males < 60 years old (85.0–
95.0 μg/l), males > 60 years old (70.0–90.0 μg/l).
Echocardiographic assessment
The transthoracic echocardiographic evaluation of the left
ventricle was performed during hospitalization and on the
follow-up visit (Philips IE 33, Amsterdam, The Netherlands)
by the same echocardiographer. Afterwards, records were
reviewed and confirmed blindly by another echocardiog-
rapher. The following parameters were analyzed: dimen-
sions, volumes and sphericity of the left ventricle (LVEDD,
LVESD, LVEDV, LVESV, SI), left ventricle ejection fraction
(LVEF), the rate of LV systolic pressure rise (+dp/dt), left
ventricle filling profile, E/E’ index (E’ was measured on
medial and lateral aspect of mitral annulus and averaged),
mitral annular plane systolic excursion (MAPSE), tricuspid
annular plane systolic excursion (TAPSE) and right ven-
tricle systolic pressure (RVSP). The incidence of moderate
or severe functional mitral valve regurgitation was assessed
according to EACVI guidelines [26].
24-h Holter ECG monitoring
24-h Holter ECG monitoring was performed during
hospitalization (Reynolds Pathfinder system, Snoqualmie,
USA). Maximal, minimal and mean sinus rhythm fre-
quency, as well as maximal and minimal ventricular rhythm
in case of atrial fibrillation or flutter were calculated during
hospitalization. In addition, heart rate variability for sinus
rhythm (HRV), severe bradycardia, atrioventricular conduc-
tion disturbances and occurrence of ventricular or supra-
ventricular arrhythmias were evaluated.
Study end-points
Major adverse events (MAE) included: resuscitated car-
diac arrest, cardiovascular death, re-hospitalization for
decompensated heart failure requiring intravenous di-
uretics and/or catecholamines administration, evidence
of ventricular tachycardia, severe sinus bradycardia or
atrioventricular blocks. We also analyzed the occurrence
of the composite endpoint of the above adverse events
and the duration of hospital stay. Each of the events was
analyzed during the hospital stay and during the
follow-up of 137.53 (±36.49) days. All patients entered
the survival analysis, including 43 participants attending
the control ambulatory visit (3 - group A, 40 – group B),
and 12 participants were contacted by phone (2 - group
A, 10 – group B). Four participants from group A died
before the scheduled follow-up visit.
Statistical analysis
Categorical variables are presented as numbers and per-
centages. Continuous variables are expressed as mean ±
standard deviation (SD) or median and interquartile range
(IQR). We assessed the normality using the Shapiro-Wilk
test. For the equality of variances, we used the Levene’s
test. Differences between groups were compared using the
Student’s or Welch’s t-test depending on the equality of
variances for normally distributed variables. We used the
Mann-Whitney U-test for non-normally distributed con-
tinuous variables. Categorical variables were compared by
the Pearson’s chi-squared test or the Fisher’s exact test if
20% of cells had an expected count of less than 5. We
used the Pearson’s test or the Spearman rank correlation
test (depending on normality) to calculate the coefficient
correlation measuring dependence. The univariate Cox
proportional hazard analysis was performed to identify
predictors of the outcomes. Receiver operating character-
istic (ROC) curves were analyzed to determine the optimal
cut-off values for parameters. We drew Kaplan-Meier
curves to analyze an event-free survival in selected risk
groups. The log-rank statistic was used to test the
differences in the outcomes between the groups. We
performed the statistical analyses with JMP®, Version
14.0.0 (SAS Institute INC., Cary, NC, USA) and using
R, Version 3.4.1 (R Core Team. R: A language and
environment for statistical computing. R Foundation
for Statistical Computing. Vienna, Austria, 2017.
https://www.r-project.org/). P-value less than 0.05 was
considered as statistically significant.
Results
Baseline characteristics of the study group are shown in
Table 1. The prevalence of low T3 syndrome was 15.3%
(n = 9) while the prevalence of selenium deficiency was
74.6% (n = 44).
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We found no difference between groups regarding age,
sex, HF etiology, comorbidities, pharmacotherapy prior to
admission, use of electrotherapy and NYHA class. Patients
with low T3 syndrome had a lower body mass index and
systolic blood pressure. They also more frequently suffered
from peripheral edema and required inotropic drugs during
their hospitalization.
The repeated analysis of the hormone levels showed that
2 patients with initially low T3 syndrome became euthyr-
oid, whereas 1 previously euthyroid patient developed low
Table 1 Baseline characteristics of study population according to fT3 concentration
Characteristics Group A
Low fT3
< 3.10 pmol/L
(n = 9)
Group B
Normal fT3
≥ 3.10 pmol/L
(n = 50)
p-value
Age, years 65.0 (58.0–78.5) 64.5 (58.5–71.5) 0.4047
Male sex, n (%) 7 (77.8%) 41 (82.0%) 0.6697
Body mass index (kg/m2) 20.8 (19.4–26.4) 30.1 (26.9–33.3) 0.0008
Main etiology of heart failure
Ischemic 4 (44.4%) 25 (50.0%) 0.7117
Valvular 2 (22.2%) 6 (12.0%)
Idiopathic/Other 3 (33.3%) 19 (38.0%)
Medical history, n (%)
Hypertension 8 (88.9%) 42 (84.0%) 1.0000
Dyslipidemia 7 (77.8%) 44 (88.0%) 0.5946
Type 2 diabetes mellitus 3 (33.3%) 23 (46.0%) 0.7176
Atrial fibrillation 4 (44.4%) 28 (56.0%) 0.7187
Smoking 3 (33.3%) 18 (36.0%) 1.0000
Medications prior to admission, n (%)
Beta blockers 8 (88.9%) 46 (92.0%) 0.5768
ACEI 4 (44.4%) 38 (76.0%) 0.1033
ARB 0 (0.0%) 3 (6.0%) 1.0000
MRA 6 (66.7%) 34 (68.0%) 1.0000
Diuretics 7 (77.8%) 45 (90.0%) 0.2880
Ivabradine 3 (33.3%) 4 (8.0%) 0.0644
Digoxin 9 (18.0%) 2 (22.2%) 0.6697
Electrotherapy prior to admission, n (%)
ICD 3 (33.3%) 14 (28.0%) 0.7080
CRT 2 (22.2%) 5 (10.0%) 0.2880
Pacemaker 1 (11.1%) 3 (6.0%) 0.4940
iv medication during hospitalization
Iv diuretics 8 (88.9%) 31 (72.1%) 0.4203
Iv inotropic drugs 6 (66.7%) 4 (8.0%) 0.0003
Initial clinical findings
Rales, n (%) 7 (77.8%) 22 (44.0%) 0.0797
Peripheral edema, n (%) 8 (88.9%) 23 (46.0%) 0.0274
Heart rate (beats/min) 88.0 (72.5–115.0) 80.0 (70.0–101.0) 0.4400
Systolic blood pressure (mmHg) 108.7 (±14.9) 129.0 (±22.8) 0.0128
Diastolic blood pressure (mmHg) 73.0 (±11.17) 82.3 (±15.2) 0.0876
NYHA class
III, n (%) 3 (33.3%) 34 (68.0%) 0.0661
IV, n (%) 6 (66.7%) 16 (32.0%)
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Table 2 Laboratory data according to serum fT3 concentration
Characteristics Group A
Low fT3
< 3.10 pmol/L
(n = 9)
Group B
Normal fT3
≥ 3.10 pmol/L
(n = 50)
p-value
TSH (1 day), μIU/ml 2.3 (0.98–3.0) 1.5 (0.9–1.9) 0.1984
TSH (3 day), μIU/ml 2.2 (1.3–3.0) 1.5 (1.2–2.0) 0.1049
fT3 (1 day), pmol/l 2.7 (±0.7) 4.4 (±0.7) <0.0001
fT3 (3 day), pmol/l 2.6 (±0.8) 4.3 (±0.6) <0.0001
fT4 (1 day), pmol/l 16.9 (±2.9) 18.1 (±3.0) 0.2455
fT4 (3 day), pmol/l 16.5 (±3.3) 17.6 (±2.4) 0.2803
fT3/fT4 ratio (1 day) 0.16 (±0.04) 0.25 (±0.05) <0.0001
fT3/fT4 ratio (3 day) 0.16 (±0.06) 0.25 (±0.04) <0.0001
rT3, ng/ml 0.18 (±0.09) 0.22 (±0.09) 0.1854
NT-proBNP (1 day), pg/ml 7330.0 (5243.0–28,033.0) 2714.5 (1762.3–5968.3) 0.0016
NT-proBNP (3 day), pg/ml 6909.0 (5143.0–21,934.5) 2027. (790.5–3378.6) <0.0001
hsCRP (1 day), mg/l 10.2 (4.5–37.0) 4.1 (1.8–9.3) 0.0369
hsCRP (3 day), mg/l 21.0 (3.6–46.0) 5.1 (1.5–8.6) 0.0269
WBC (1 day), 10^3 7.3 (5.5–9.7) 7.9 (6.3–9.3) 0.5692
WBC (3 day), 10^3 7.6 (5.4–10.6) 7.1 (6.1–7.7) 0.4932
Selenium, μg/l 58.2 (31.7–71.0) 59.7 (47.9–71.2) 0.4735
Creatinine (1 day), μmol/l 109.0 (77.5–121.5) 103.0 (81.5–123.0) 0.8720
eGFR/CKD-EPI/ (1 day) 66.0 (52.0–81.0) 64.0 (50.0–84.0) 0.7553
Table 3 Echocardiographic data of study population according to fT3 concentration
Characteristics Group A
Low fT3
< 3.10 pml/L
(n = 9)
Group B
Normal fT3
≥3.10 pmol/L
(n = 50)
p-value
LVEDD, mm 65.5 (±12.7) 65.6 (±9.9) 0.9483
LVESD, mm 59.0 (±14.0) 55.9 (±11.4) 0.4692
LVEDV, ml 212.9 (±83.4) 238.4 (±86.8) 0.4187
LVESV, ml 178.8 (±76.3) 184.6 (±78.9) 0.8386
SI 0.6 (±0.07) 0.64 (±0.12) 0.3395
LVEF, % 16.1 (±5.7) 25.4 (±7.4) 0.0008
MAPSE, mm 4.0 (3.6–4.8) 7.0 (5.0–8.9) 0.0051
E/A 2.7 (2.2–3.2) 1.3 (0.8–2.2) 0.0082
Number of pts. with restrictive
mitral filling pattern, n (%)
5 (8.3%) 13 (46.4%) 0.1801
E/E’ 15.2 (±5.6) 17.5 (±8.5) 0.4321
RVSP, mmHg 44.0 (39.0–62.5) 35.0 (31.0–48.5) 0.0794
TAPSE, mm 12.8 (±4.8) 15.8 (±5.0) 0.1066
+dP/dt, mmHg/s 466.0 (404.5–824.5) 606.0 (457.0–757.0) 0.4222
Functional mitral regurgitation, n (%) 5 (55.6%) 21 (42.0%) 0.4885
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T3 syndrome. Additionally, 1 previously euthyroid patient
developed hyperthyroidism.
Laboratory and echocardiographic data are presented
in Table 2 and Table 3.
Patients with low fT3 presented: lower fT3/fT4 ra-
tio, higher levels of NT-proBNP and hsCRP. There
was a non-significant tendency for lower Se levels in
the low fT3 group. In the low fT3 group we observed
a higher mitral inflow, E/A ratio but lower LVEF and
MAPSE.
On the follow-up visit laboratory tests and echocardi-
ography were performed but results were not analyzed
because of a limited number of survivors in group A (4
patients died before the scheduled visit).
We found no differences between the low fT3 group
and normal fT3 group in parameters analyzed during 24-h
ECG monitoring: max. HR (medians, 95.0 [88.5–106.5] vs.
99.0 [87.0–116.3], p = 0.5477), min. HR (60.3 ± 10.6 vs.
63.3 ± 11.1, p = 0.4634), med. HR (74.2 ± 1. vs. 77.2 ± 13.6,
p = 0.5409), HRV (p = 0.8897), number of premature
ventricular contractions (medians, 2887.0 [416.5–10,197.5]
vs. 871.5 [137.3–3055.5], p = 0.1912), occurrence of non-
sustained ventricular tachycardia (6 [66.7%] vs. 34 [68.0%],
p = 1.0), occurrence of sustained ventricular tachycardia
(0.0% vs. 0.0%), number of premature supraventricular
contractions (medians, 0.0 [0.0–288.0] vs. 3.50 [0.0–
163.3], p = 0.9552), occurrence of supraventricular tachy-
cardia (2 [22.2%] vs. 19 [38.0%], p = 0.4687), occurrence of
severe bradycardia (0.0% vs. 0.0%) and occurrence of atrio-
ventricular block type II Mobitz II or type III (0 [0.0%] vs.
1 [2.0%], p = 1).
Correlations between fT3 concentration, fT3/fT4 ratio
and main clinical variables are shown in Table 4.
The hospital stay in the low fT3 group was longer in
comparison to the normal fT3 group (medians, 18.0
[14.5–36.5] vs. 5.0 [4.0–8.3], p = < 0.0001). Endpoints
were more frequent in the low fT3 group: in-hospital
mortality (33% vs. 0.0%, p = 0.0026), resuscitated cardiac
arrest (2% vs 33.3%, p = 0.0095), cardiovascular death
(44.4% vs. 0.0%, p = 0.0003).
A univariate analysis revealed that fT3 and fT3/fT4 ratio
were predictors of survival (Table 5). Unfortunately, a
multivariate analysis was not possible due to a limited
sample size.
Kaplan-Meier survival curves for cardiovascular death and
MAE in patients with low fT3 vs. normal fT3 are shown in
Fig. 1 and in patients with low fT3/fT4 ratio vs. normal fT3/
fT4 ratio in Fig. 2. The cutoff point of fT3 was 3.1 pmol/l (la-
boratory norm). The optimal cutoff point of fT3/fT4 ratio
(calculated by ROC curve analysis) was 0.206 for both car-
diovascular mortality and MAE. The Kaplan-Meier survival
curves indicate marked differences between the groups.
Discussion
Our results show that low fT3 concentration is
frequently found in severe HF patients (15.3%). Of note,
as TSH and fT4 remained normal, low T3 may be missed
if only routine TSH measurement is done. This seems to
be an important finding, as Group A, in comparison to
Group B, presented not only worse initial clinical findings,
laboratory and echocardiographic parameters (pivotal in
assessment of HF severity) but also an unfavorable HF
course. The significance of fT3/fT4 ratio was also found by
Kozdag et al., who proved that it is an independent prog-
nostic marker in HF [27]. In our study, a univariate analysis
revealed that the fT3 and fT3/fT4 ratio is associated with a
poorer prognosis in HF. The Kaplan-Meier survival curves
showed that the death-free survival probability and MAE-
free survival probability are lower amongst patients with a
lower fT3 and fT3/fT4 ratio. Our findings are consistent
with previous research [20, 22–24, 27].
Table 4 Correlation analysis
Variable By variable Correlation p-value
fT3 hsCRP −0.4505 0.0003
fT3 selenium 0.2265 0.0846
fT3 NT-proBNP −0.5368 <0.0001
fT3 LVEF 0.4311 0.0007
fT3 MAPSE 0.2819 0.0305
fT3 +dp/dt 0.2981 0.0467
fT3 TAPSE 0.3345 0.0096
fT3 E/A −0.4496 0.0087
fT3/fT4 hsCRP −0.4855 <0.0001
fT3/fT4 selenium 0.1139 0.3906
fT3/fT4 NT-proBNP −0.5408 <0.0001
fT3/fT4 LVEF 0.4865 <0.0001
fT3/fT4 MAPSE 0.3341 0.0097
fT3/fT4 +dp/dt 0.4831 0.0079
fT3/fT4 TAPSE 0.2837 0.0295
fT3/fT4 E/A −0.4552 0.0078
Table 5 Univariate analysis of predictors for cardio-vascular
mortality
Univariate
Variable HR per HR (95% CI) p-value
fT3 (1 day), pmol/l 1 0.230 (0.060–0.649) 0.0051
fT3 (3 day), pmol/l 1 0.249 (0.090–0.619) 0.0036
fT3/fT4 ratio (1 day) 0.1 0.079 (0.006–0.560) 0.0101
fT3/fT4 ratio (3 day) 0.1 0.073 (0.007–0.436) 0.0038
NT-proBNP (1 day), pg/ml 1000 1.102 (1.012–1.197) 0.0290
NT-proBNP (3 day), pg/ml 1000 1.144 (1.043–1.257) 0.0074
LVEF, % 1 0.768 (0.577–0.929) 0.0033
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Low fT3 levels and fT3/fT4 ratio are associated with
more advanced HF, reflected by echocardiographic vari-
ables. Another finding was a high incidence of selenium
deficiency in our HF patients (74.6%). However, we
could not prove correlation between selenium concen-
tration and fT3 levels. Thus, our hypothesis of Se defi-
ciency being a cause of impaired TH conversion could
not be confirmed and the mechanism of low fT3 syn-
drome in HF patients remains controversial. Our study
is the first to date testing the correlation between Se and
fT3 levels in HF patients. The negative result is an
argument against the hypothesized role of Se deficiency
as an important contributor of low T3 syndrome. How-
ever, our study confirms a high incidence of selenium
deficiency in HF patients and the importance of this
phenomenon deserves further research.
The correlation between fT3 and hsCRP levels in our
study may indicate that inflammation may contribute to
impaired TH conversion. Our observations are consist-
ent with Lubrano et al. [28].
Our study documents the importance of low fT3 levels
being linked to HF severity and a poor prognosis. Inter-
estingly, heart transplantation is associated with
normalization of low T3 levels [21]. Low fT3 levels may
be the result of severe multiorgan syndrome of HF. Fu-
ture studies in larger groups are needed to evaluate the
independent prognostic value of low T3. On the other
hand, we cannot exclude the possibility that low T3 syn-
drome itself may worsen the HF course and if such a
concept is proven, a low fT3 level may become a novel
therapeutic target in HF. Few publications analyzed T3
supplementation in HF. Research by Hamilton et al.
revealed that intravenous T3 supplementation in 23
selected patients with advanced HF and low T3 levels is
well tolerated without episodes of ischemia or clinical
arrhythmia and an increase in mean metabolic rate
assessed by indirect calorimetry. T3 supplementation
does not affect mean arterial blood pressure and heart
rate. Nevertheless, it causes a significant increase in
cardiac output with a reduction in systemic vascular
Fig. 1 Kaplan-Meier survival curves for patients with low fT3 vs. normal fT3
Fig. 2 Kaplan-Meier survival curves for patients with low T3/fT4 ratio vs. normal fT3/fT4 ratio
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resistance [29]. In addition, Pingitore et al. showed that
intravenous T3 replacement therapy causes a decrease in
heart rate, an increase in left ventricular diastolic volume
and stroke volume, as well as an improvement of a neuro-
hormonal profile: a decrease of plasma noradrenaline,
NT-proBNP and aldosterone [30]. Amin et al. [31] proved
that lowering of NT-proBNP and hsCRP levels may be
accompanied by an increase in LVEF and 6-min walk
distance. Another study conducted by Holmager et al. [32]
concerning oral T3 supplementation did not support
the hypothesis of T3 supplementation in chronic HF.
However, in that study, the sample size was also small
(only 13 participants completed the protocol) and not
representative, so there is no definite answer as to
whether such an approach may be beneficial and
further studies are needed.
Our study has several strengths and limitations. One
advantage is the prospective character of the protocol
and very strict inclusion criteria. Unlike other cited
studies, this approach allowed the creation of a very
homogenous group with exclusion of subclinical
hypothyroidism and many common factors potentially
influencing the thyroid status. On the other hand, such
narrow criteria made the study population relatively
small and did not enable a significant multivariate
analysis of the prognostic value of low fT3 levels.
Conclusions
Low T3 syndrome is frequently found in patients with
HFrEF and is associated with a poor outcome. Selenium
deficiency is highly prevalent in severe HF patients, but
we did not identify any significant correlation between
selenium and fT3 levels. Further studies concerning the
mechanisms and importance of low fT3 level in the
heart failure population are needed.
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